PSI Advisors LLC Sells 4,859 Shares of Pfizer Inc. (NYSE:PFE)

PSI Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,964 shares of the biopharmaceutical company’s stock after selling 4,859 shares during the period. PSI Advisors LLC’s holdings in Pfizer were worth $582,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the fourth quarter valued at about $30,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.00 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The business’s 50 day moving average price is $23.14 and its two-hundred day moving average price is $24.93. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $136.47 billion, a PE ratio of 17.39, a price-to-earnings-growth ratio of 0.89 and a beta of 0.57.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the business earned $0.82 earnings per share. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.17%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.